New drug ASKG915 tested in advanced cancer patients

NCT ID NCT05867420

First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This study tests a new drug called ASKG915, alone or with standard treatments, in people with advanced solid tumors that have not responded to other therapies. The main goals are to check safety and find the right dose. About 594 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 201321, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University Cancer Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100089, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

Conditions

Explore the condition pages connected to this study.